Bisphosphonates as a therapeutic choice for multifocal epithelioid hemangioma of bone: A case report
Conclusions:
EH of multiple bones responded favorably to intravenous Zometa with improvement of bone metabolic markers. After 1 year on follow-up, the patient was doing well with no significant pain. We suggest that bisphosphonates should be considered in the treatment of multifocal osteolytic EH of bone.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Back Pain | Bone Graft | Cancer & Oncology | Carcinoma | CT Scan | Hemangioma | Internal Medicine | Pain | Pain Management | PET Scan | Reclast | Vertebroplasty | Zometa